Phase 4 N=100 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Heart Failure
Primary: Cummulative Incidence of Events at Week 26 — 35.6; 43.8 Percentage of events at 26 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Acupuncture and Auditory Evoked Potentials
Evoked Potentials · Healthy Volunteers
Primary: Latencies of Auditory Evoked Potentials — 255; 255 ms
N/A N=120 Prophylactic Incisional Care in Obese Women at Cesarean
Wound Infections
Primary: Number of Participants With Composite Surgical Site Infection (SSI) or Other Wound Complication. — 5; 3 Participants — p=0.72
Phase 2 N=24 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants
Phase 3 N=209 FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43
Phase 2 N=185 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Refractory Chronic Cough
Primary: Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo) — -0.18; -0.45 coughs/hr — p=0.9942
Phase 3 N=907 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Lung Cancer
Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693
N/A N=51 Efficacy Study of an Unloading Brace for Knee Osteoarthritis
Osteoarthritis of the Knee
Primary: Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Score — 2.92; 2.86; 3.03; 2.67 units on a scale — p=<0.05
N/A N=81 To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
Acute Hepatitis C · HIV · HIV Infections
Primary: Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection — 0.18; 0.22 binding potential ratio
Phase 4 N=120 The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
Diabetes Mellitus, Type 2 · Diabetes
Primary: Mean Change From Randomization in A1c at Week 26 — 3.4; 4.1 Percentage of glycosylated hemoglobin
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
Phase 2 N=124 A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Chronic Renal Failure
Primary: Change From Baseline in Daily Urine Volume — 169.2; 111.8; -259.9 mL
N/A N=479 Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX
Rheumatoid Arthritis
Primary: Number of Participants as Per Type of Insurance Plan — 36; 13; 9; 301 Participants
Phase 2 N=347 Phase I/II Hypofractionated Radiotherapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants Who Experience Grade 3 or Higher Acute Toxicities — 1; 1; 0 Participants
Phase 2 N=235 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
Primary: Change From Baseline in MQC on Liver Biopsy at Week 96 — -0.5; 0.5; 0.0 percentage of MQC